| Jasper Therapeutics to Present at Upcoming Investor Conferences |
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate in the following investor conferences: |
globenewswire.com |
2025-05-14 20:30:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update |
REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended March 31, 2025 and provided a corporate update. |
globenewswire.com |
2025-05-12 20:05:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting |
REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, is presenting updated clinical data from the Phase 1b/2a BEACON study, as well as data from four preclinical studies evaluating briquilimab, at the AAAAI 2025 Annual Meeting, being held February 28 - March 3, 2025, in San Diego, CA. |
globenewswire.com |
2025-03-01 14:45:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting |
REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced a late-breaking oral presentation of briquilimab data from the Phase 1b/2a BEACON in CSU study at the 2025 AAD Annual Meeting, being held March 7 - 11, 2025, in Orlando, FL. The presentation will consist of data from patients included in the Company's January 8th, 2025, disclosure of preliminary data from the BEACON study. |
globenewswire.com |
2025-02-28 10:00:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update |
REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter and year ended December 31, 2024 and provided a corporate update. |
globenewswire.com |
2025-02-27 10:00:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics to Present at Upcoming March Investor Conferences |
REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate in the following investor conferences in March. |
globenewswire.com |
2025-02-25 18:30:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting |
REDWOOD CITY, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced five poster presentations and an oral presentation of briquilimab data at the AAAAI 2025 Annual Meeting, being held February 28 - March 3, 2025, in San Diego, CA. The oral presentation and one of the poster presentations will include additional follow-up from patients included in the Company's January 8th, 2025, disclosure of preliminary data from the Phase 1b/2a BEACON trial evaluating briquilimab in CSU. |
globenewswire.com |
2025-02-10 10:00:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference |
REDWOOD CITY, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that its management will present at the Oppenheimer Healthcare Life Sciences Conference, taking place February 11-12, 2025. |
globenewswire.com |
2025-02-04 18:30:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria |
Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile |
globenewswire.com |
2025-01-08 09:00:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025 |
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that Jasper will host a virtual webinar on Wednesday, January 8, 2025, to present preliminary data from the BEACON study of briquilimab in CSU. |
globenewswire.com |
2025-01-06 10:00:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma |
REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that the first patient has been dosed in Jasper's Phase 1b/2a clinical challenge study evaluating briquilimab in allergic asthma, called ETESIAN (Evaluating The Efficacy and Safety of briquilimab In participANts with allergic asthma). The ETESIAN study is evaluating a single administration of subcutaneous briquilimab in patients with asthma. |
globenewswire.com |
2024-12-02 18:30:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma |
Jasper Therapeutics, Inc.'s Briquilimab shows promise in treating chronic urticaria and asthma, with potential market approval by 2027, offering significant revenue opportunities in large, underserved markets. Despite positive preliminary clinical results, Jasper faces financial risks, needing additional funds by Q3 2025, which may lead to shareholder dilution. Analysts rate JSPR as a strong buy with a $69.5 target, but caution is advised due to the speculative nature and financial instability. |
seekingalpha.com |
2024-11-18 12:09:39 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics to Participate at Upcoming Investor Conferences |
REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that it will participate in the following investor conferences: |
globenewswire.com |
2024-11-13 18:30:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended September 30, 2024, provided a corporate update and announced the closure of Jasper's legacy clinical study in lower-risk myelodysplastic syndromes (LR-MDS). |
globenewswire.com |
2024-11-07 09:30:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting |
REDWOOD CITY, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, is presenting data from preclinical studies evaluating briquilimab at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, taking place October 24-28, 2024, in Boston, Massachusetts. |
globenewswire.com |
2024-10-24 12:00:00 |
Czytaj oryginał (ang.) |
| Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday? |
On Monday, Jasper Therapeutics Inc JSPR stock is trading higher after the company reported preliminary data from its ongoing SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with cold urticaria (ColdU) or symptomatic dermographism (SD). |
benzinga.com |
2024-10-14 13:22:52 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria |
14 of 15 participants enrolled achieved a clinical response 10 of 12 participants in the 120mg cohort achieved a complete response No serious adverse events; no grade 3 or higher adverse events reported Initial data from BEACON study expected week of January 6 th , 2025, including 180mg Q8W cohort Company to host conference call and webinar today at 8:00 a.m. EDT REDWOOD CITY, Calif. |
globenewswire.com |
2024-10-14 11:00:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma |
REDWOOD CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that Health Canada has cleared the Company's Clinical Trial Application (CTA) for a Phase 1b/2a asthma challenge study evaluating briquilimab in asthma. |
globenewswire.com |
2024-09-10 11:30:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences |
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that it will participate in the following investor conferences in September: |
globenewswire.com |
2024-09-04 20:30:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments |
Enrollment in BEACON and SPOTLIGHT studies progressing faster than expected; enrollment in the 240mg single-dose cohort of the BEACON study ongoing |
globenewswire.com |
2024-08-13 11:00:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors |
REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced the appointment of Svetlana Lucas, Ph.D., to Jasper's Board of Directors (the Board), effective as of June 18, 2024. Separately, Anna French, D. Phil., stepped down from the Board, effective as of June 18, 2024. |
globenewswire.com |
2024-06-19 12:00:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit |
REDWOOD CITY, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced today announced that its management will present at the Oppenheimer Novel Targets in Immunology Summit, to be held on Monday, June 24, 2024, in New York City. |
globenewswire.com |
2024-06-17 20:30:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress |
REDWOOD CITY, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today is presenting preclinical data demonstrating the effect of briquilimab on hematopoietic stem cells (HSCs) at the European Hematology Association (EHA) Hybrid Congress, being held June 13 – 16, 2024 in Madrid, Spain. |
globenewswire.com |
2024-06-14 12:00:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024 |
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced presentations of data from its preclinical and healthy volunteer studies of briquilimab, as well as trial-in-progress presentations from its BEACON and SPOTLIGHT clinical studies, at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, taking place May 31 – June 3 in Valencia, Spain. |
globenewswire.com |
2024-05-30 22:05:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference |
REDWOOD CITY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that its management will present at the Jefferies Global Healthcare Conference at 4:00pm EDT on Wednesday, June 5, 2024. |
globenewswire.com |
2024-05-29 20:30:00 |
Czytaj oryginał (ang.) |
| Equities Analysts Offer Predictions for Jasper Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:JSPR) |
Jasper Therapeutics, Inc. (NASDAQ:JSPR – Free Report) – Equities research analysts at Capital One Financial upped their Q2 2024 earnings per share estimates for shares of Jasper Therapeutics in a research report issued on Wednesday, May 15th. Capital One Financial analyst T. Chiang now anticipates that the company will post earnings per share of ($1.19) for the quarter, up from their prior estimate of ($1.24). The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.35) per share. Capital One Financial also issued estimates for Jasper Therapeutics’ FY2024 earnings at ($4.64) EPS, FY2025 earnings at ($5.08) EPS, FY2026 earnings at ($5.58) EPS, FY2027 earnings at ($2.74) EPS and FY2028 earnings at $2.23 EPS. A number of other equities research analysts also recently commented on JSPR. Oppenheimer reiterated an “outperform” rating and set a $80.00 price objective on shares of Jasper Therapeutics in a research report on Thursday, March 7th. Evercore ISI started coverage on Jasper Therapeutics in a report on Wednesday, April 3rd. They set an “outperform” rating and a $65.00 target price for the company. TD Cowen assumed coverage on Jasper Therapeutics in a research note on Monday, March 18th. They issued an “outperform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research note on Wednesday, May 15th. Finally, Royal Bank of Canada began coverage on shares of Jasper Therapeutics in a research report on Thursday, March 28th. They issued an “outperform” rating and a $70.00 target price on the stock. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $64.29. Read Our Latest Stock Report on JSPR Jasper Therapeutics Price Performance JSPR stock opened at $23.02 on Monday. The firm has a market cap of $346.68 million, a PE ratio of -4.09 and a beta of 2.25. Jasper Therapeutics has a 12 month low of $4.00 and a 12 month high of $31.01. The firm has a 50 day simple moving average of $25.12 and a 200 day simple moving average of $15.85. Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) last posted its quarterly earnings data on Monday, March 4th. The company reported ($1.50) earnings per share for the quarter, beating the consensus estimate of ($1.65) by $0.15. Institutional Investors Weigh In On Jasper Therapeutics A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JSPR. Opaleye Management Inc. acquired a new position in shares of Jasper Therapeutics in the fourth quarter worth $3,144,000. Kingdon Capital Management L.L.C. grew its stake in Jasper Therapeutics by 16.4% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock valued at $2,793,000 after purchasing an additional 500,000 shares in the last quarter. Monaco Asset Management SAM acquired a new position in Jasper Therapeutics in the 4th quarter worth about $197,000. Cowen AND Company LLC purchased a new stake in shares of Jasper Therapeutics during the 3rd quarter worth about $140,000. Finally, StemPoint Capital LP acquired a new stake in shares of Jasper Therapeutics during the 1st quarter valued at about $3,794,000. Hedge funds and other institutional investors own 79.85% of the company’s stock. Jasper Therapeutics Company Profile (Get Free Report) Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. Read More Five stocks we like better than Jasper Therapeutics What is the Euro STOXX 50 Index? MarketBeat Week in Review – 5/13 – 5/17 Low PE Growth Stocks: Unlocking Investment Opportunities Take-Two Interactive Software Offers 2nd Chance for Investors How to Effectively Use the MarketBeat Ratings Screener Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook |
https://www.defenseworld.net |
2024-05-20 05:38:46 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments |
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced results for the fiscal quarter ended March 31, 2024, and reported recent corporate developments. |
globenewswire.com |
2024-05-14 12:00:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics Announces Briquilimab Development Program in Asthma |
REDWOOD CITY, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced the expansion of its mast cell development portfolio with a Phase 1b/2a study evaluating briquilimab in asthma patients that is expected to begin enrolling in the fourth quarter of 2024. |
globenewswire.com |
2024-05-13 12:00:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics to Present at Upcoming Investor Conferences in May |
REDWOOD CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the following upcoming investor conferences in May: |
globenewswire.com |
2024-05-07 20:30:00 |
Czytaj oryginał (ang.) |
| Jasper Therapeutics (JSPR) Upgraded to Buy: Here's What You Should Know |
Jasper Therapeutics (JSPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-05-07 17:01:13 |
Czytaj oryginał (ang.) |